Novo Nordisk debuts Ozempic at ₹2,200 a week

Danish drugmaker Novo Nordisk on Friday launched its blockbuster diabetes drug Ozempic in India, with a starting price of ₹2,200 per week.

- Jessica Jani

For a four-week course, the entry 0.25mg dose will be priced at ₹8,800, positioning the drug squarely in the premium bracket for India’s fast-growing obesity and metabolic-health market.

The launch comes close on the heels of Wegovy, Novo's dedicated weight-loss injection, which entered the market in June.

“It was a very tough decision to bring Ozempic at this price, with a starting cost of ₹2,200 per week for the 0.25mg dose,” Novo Nordisk India managing director Vikrant Shrotriya said at the launch, adding that the company wants more people to benefit from the medicine at an affordable rate when prescribed by doctors in the fight against diabetes and obesity.

India’s nascent anti-obesity drug market is heating up. Eli Lilly’s Mounjaro has taken an early lead since its March launch, becoming a top-selling drug by October. Novo faces additional competitive pressure next year, as semaglutide—the compound behind Ozempic and Wegovy—loses patent exclusivity in March 2026, paving the way for cheaper domestic generics.